Application
Fig6: Flow cytometric analysis of Hela cells with BCL2L10 antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).Application
Fig6: Flow cytometric analysis of Hela cells with BCL2L10 antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).Application
Fig6: Flow cytometric analysis of Hela cells with BCL2L10 antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).Application
Fig6: Flow cytometric analysis of Hela cells with BCL2L10 antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).Application
Fig6: Flow cytometric analysis of Hela cells with BCL2L10 antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).Application
Fig6: Flow cytometric analysis of Hela cells with BCL2L10 antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).| Product Name | BCL2L10 [F9-A2] |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | Anti apoptotic protein NrH antibody Anti-apoptotic protein NrH antibody Apoptosis regulator Bcl B antibody Apoptosis regulator Bcl-B antibody B2L10_HUMAN antibody BCL B antibody Bcl-2-like protein 10 antibody Bcl2 L 10 antibody BCL2 like 10 (apoptosis facilitator) antibody BCL2 like 10 protein antibody Bcl2-L-10 antibody Bcl2l10 antibody BCLB antibody Boo antibody Diva antibody MGC129810 antibody MGC129811 antibody Nrh antibody |
| Product description | Members of the Bcl-2 family of proteins regulate cell survival by either inhibiting apoptosis or by facilitating the complicated process of cell death. Bcl-B, also known as BCL2L10, Diva, Boo or BCLB, is a widely expressed 194 amino acid member of the Bcl-2 protein family. Localized to the nuclear membrane, Bcl-B promotes cell survival by suppressing BAX-induced apoptosis. Bcl-2 contains a BH4 domain as well as a transmembrane domain, both of which are necessary for its antiapoptotic effects. Overexpression of Bcl-B is thought to prevent the release of cytochrome C from the mitochondria, thereby triggering caspase-3 activation and suppressing cell apoptosis. Bcl-B is implicated in the pathogenesis of cervical cancer. |
| Immunogen | Recombinant protein |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG1 |
| Host Species | Mouse |
| Tested Applications | WBICCIHCFC |
| WB:1:500-1:2,000 ICC:1:50-1:200 IHC:1:100-1:200 FC:1:100-1:200 |
|
| Species Reactivity | Human |
| Concentration | 2mg/ml |
| Alternative Names | Anti apoptotic protein NrH antibody Anti-apoptotic protein NrH antibody Apoptosis regulator Bcl B antibody Apoptosis regulator Bcl-B antibody B2L10_HUMAN antibody BCL B antibody Bcl-2-like protein 10 antibody Bcl2 L 10 antibody BCL2 like 10 (apoptosis facilitator) antibody BCL2 like 10 protein antibody Bcl2-L-10 antibody Bcl2l10 antibody BCLB antibody Boo antibody Diva antibody MGC129810 antibody MGC129811 antibody Nrh antibody |
|---|---|
| Molecular Weight(MW) | 22 kDa |
| Cellular Localization | Mitochondrion. Nucleus membrane. |
| SwissProt ID | Q9HD36 |
|---|
Application
Fig6: Flow cytometric analysis of Hela cells with BCL2L10 antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).
Application
Fig6: Flow cytometric analysis of Hela cells with BCL2L10 antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).
Application
Fig6: Flow cytometric analysis of Hela cells with BCL2L10 antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).
Application
Fig6: Flow cytometric analysis of Hela cells with BCL2L10 antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).
Application
Fig6: Flow cytometric analysis of Hela cells with BCL2L10 antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).
Application
Fig6: Flow cytometric analysis of Hela cells with BCL2L10 antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).| Positive Control | Human BCL2L10 recombinant protein, BCL2L10-hIgGFc transfected HEK293 cell lysate, Hela, human lung cancer tissue, human cervical cancer tissue. |
|---|---|
| Application Notes | WB:1:500-1:2,000 ICC:1:50-1:200 IHC:1:100-1:200 FC:1:100-1:200 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
